The US Food and Drug Administration (FDA) has approved a product known as enzalutamide (Xtandi®) to be used in a new way. The body, after an in-depth review says that it is ideal for handling a condition called prostate cancer (mHSPC). A close outlook Sometime back, the company gave its approval to the product for […]
FDA
Recent Posts
Rogue Station Companies/Everdime, Inc. Acquires Show Homes Business and Intellectual Property
Splash Beverage Group Gains New Distribution with Convenience Store Chain Brewer Oil Company for TapouT Distribution Across New Mexico
BEBUZEE, INC. (OTC Pink: ENGA) Plans To File RegA Next Week
Metatron Announces Deal with Health and Lifestyle Company Good Karma Global
IQST – iQSTEL Announces 47% YTD Preliminary Revenue Growth Results To $43.4 M
